Aarti Drugs gets EIR from USFDA for Maharashtra API manufacturing facility

24 Dec 2024 Evaluate

Aarti Drugs has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its API manufacturing facility located at MIDC, Tarapur, Maharashtra. 

In September 2024, USFDA had concluded inspection at said facility. On conclusion of the inspection, the company had received 7 inspectional observations in Form 483, where none of the observations are related to Data Integrity. 

Aarti Drugs is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science.

Aarti Drugs Share Price

455.75 0.10 (0.02%)
02-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1878.00
Dr. Reddys Lab 1373.70
Cipla 1537.55
Lupin 2396.30
Zydus Lifesciences 990.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.